UroAlerts - Prostate Cancer Weekly

April 07, 2026

Videos

Peer-to-Peer Clinical Conversations

Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor

Oliver Sartor

Zachary Klaassen hosts Oliver Sartor to discuss the real-world implementation of lutetium PSMA-617 following PSMAfore trial approval in the pre-chemotherapy metastatic castration-resistant prostate cancer setting.

CAPItello-281: Targeting the AKT Pathway in PTEN-Deficient mHSPC Presentation - Daniel George

Daniel George

Daniel George presents the CAPItello-281 study examining capivasertib combined with abiraterone in PTEN-deficient metastatic hormone-sensitive prostate cancer.

Beyond the Abstracts

Diagnostic Performance of Biparametric versus Multiparametric Magnetic Resonance Imaging for Prostate Cancer Diagnosis: An Updated Systematic Review and Meta-analysis - Beyond the Abstract

Molecular Pathology of Rare Histologic Variants and Treatment-Resistant Lineages of Prostate Cancer - Beyond the Abstract

Conference Coverage

PSMA and Beyond 2026: The Expanding Theranostic Dream: From Hype to Hard Truths

EAU 2026: Validation of the EAU Favorable and Unfavorable Intermediate-Risk Prognostic Groups for Predicting Biochemical Recurrence After Radical Prostatectomy in Contemporary Prostate Cancer Patients: The Added Value of MRI-Features

EAU 2026: TRAIN: A Phase III Randomized Controlled Clinical Trial of Radiotherapy with Radiosensitization Versus Intravesical BCG Therapy for High Risk NMIBC

EAU 2026: ARTO Trial: Long-Term Overall Survival Analysis from a Randomized Phase II Trial Testing the Benefit of SBRT Addition to Abiraterone in Oligometastatic CRPC Patients

ASCO GU 2026: Community Social Vulnerability and Clinical Risk-Based Care Implementation for Black Men with Prostate Cancer Treated in

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Simulation-Free Adaptive Prostate SBRT on MR-Linac: Technical Feasibility and Clinical Experience.

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer - Beyond the Abstract

Predictive factors for biochemical recurrence after radical prostatectomy in ISUP Grade Group 1 prostate cancer: a retrospective cohort with long-term follow-up.

Motivations and experiences of high-risk men in risk-adapted prostate cancer early detection: A qualitative study.

European Society of Urogenital Radiology (ESUR) perspectives on the role of prostate MRI in active surveillance.

Androgen receptor splice variant 7 expression levels distinguish AR-mutated from nonmutated metastatic castration-resistant prostate cancers.

Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells.

The impact of prostate size on single-port robot-assisted radical prostatectomy surgical outcomes.

Radiopharmaceutical Therapy in Oncology: Perspectives from Transatlantic Experts.

A single-cell and spatial atlas of prostate cancer reveals the combinatorial nature of gene modules underlying lineage plasticity and metastasis.

Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review.

Dosimetry Analysis of 177Lu-PSMA-I&T in Patients with Low-Volume Oligometastatic Hormone-Sensitive Prostate Cancer: A Secondary Analysis of the LUNAR Trial.

[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study.

[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 study.

Diagnostic assessment of artificial intelligence reconstruction on accelerated prostate MRI: a retrospective, paired, multi-reader multi-case study.

Prostate Cancer Foundation and Hästens Launch Global Health Award to Expand Prostate Cancer Care in Emerging Countries

Cytoplasmic versus nuclear localization of androgen receptor splice variant 7 as a predictor of benefit from androgen receptor pathway inhibitors in metastatic castration-resistant prostate cancer (PROPHECY trial).

First-in-Human Combination of Lead-212-Labeled PSMA Radioligand Therapy and Metabotropic Glutamate Receptor Inhibitor Riluzole as Radiosensitizer in Metastatic Castration-resistant Prostate Cancer.

Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi Panel.

Patterns and Predictors of Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Detected Local Recurrence Following Postprostatectomy Salvage Radiotherapy for Prostate Cancer.

Optimal management of oligometastatic prostate cancer: current state and future directions.

A Two-Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone-Sensitive Prostate Cancer.

Evaluating the Continuity of Telehealth Usage Among Hispanics: The Impact of Language Barriers.

Ultra-Hypofractionated versus Conventionally Fractionated Radiotherapy for Localised Prostate Cancer (HYPO-RT-PC): 10-Year Outcomes of an Open-Label, Randomised, Phase 3, Non-Inferiority Trial - Beyond the Abstract

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.

Imaging Features That Predict Indeterminate Bone Lesion Outcomes on 18F-DCFPyL PSMA PET/CT Scan: A Multicenter Cohort of 42 Biopsy-Proven Lesions.

Implementation of a Telehealth-Based Rapid Access Program for the Evaluation of Men Referred for Elevated PSA.

AURKA inhibitor VIC-1911 induces mitotic defects and functional BRCAness, sensitizing prostate cancer to PARP inhibition.

Proliferation associates with greater sensitivity to androgen receptor pathway inhibition for metastatic prostate cancer.

Testosterone-Sparing Treatment Strategies for Biochemically Recurrent Prostate Cancer After Radical Prostatectomy.

Early detection of prostate cancer-recommendations of the updated S3 guideline 2025.

PSMA PET/CT-derived Tumor Volume for Predicting Outcomes in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617.

PD-1/PD-L1 for prostate cancer: from clinical trials to practice.

Number of risk factors versus infection after transrectal prostate biopsy: a nationwide population-based study.

Association of Natural Disasters on Trends of County-Level Prostate-Specific Antigen (PSA) Screening.

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2026 Digital Science Press, LLC